Market Newsdesk

Company announcement – No. 64 / 2020

Copenhagen, December 31, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Order on Issuers’ Disclosure Obligations, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. 

In Company announcement No. 60/2020 from December 11, 2020, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including December 31, 2020.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go^®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.  

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Mads Kronborg
Head of Investor Relations & Communication
Phone: +45 5060 3707
Email: [email protected]

For U.S. Media

David Rosen
Argot Partners
Phone: 212-600-1902
Email: [email protected]

Attachment

• 64-2020 Total number of shares and voting rights in Zealand Pharma at December 31, 2020

NEW YORK, Dec. 31, 2020 (GLOBE NEWSWIRE) — Hudson Capital Inc. (NASDAQ: HUSN) (Hudson Capital) announced that FreightHub, Inc. (Fr8Hub), a North American transportation logistics technology platform company focused on US-Mexico cross-border shipping with which Hudson Capital has signed a definitive Merger Agreement, releases financial results for the three- month and nine-month periods ended September 30, 2020, in Hudson Capital’s amended Registration Statement on Form S-4 filed on December 31, 2020 with the SEC.

Javier Selgas, CEO of Fr8Hub, said, “Fr8Hub’s new product offerings, together with a more highly trained and focused salesforce, were the reasons for the revenue increase by 138% for the third quarter and 84% for the nine months ended September 30, 2020, as compared to the prior year periods. Our fourth quarter 2020, we believe, will be especially robust, with full year revenue expected to more than double 2019 revenue.”

Third quarter of 2020 revenues were $2.7 million, up 138% compared to $1.1 million in the prior year period. Revenues for the nine-month period ending September 30, 2020, were $5.4 million, up 84% compared to $2.9 million for the prior year period.

For more information about Fr8Hub’s financial results, investors are advised to review the three-month and nine-month financial results for the period ended September 30, 2020 included in Hudson Capital’s amended Registration Statement on Form S-4 filed on December 31, 2020, with the SEC.

About FreightHub, Inc.

FreightHub, Inc. (Fr8Hub) makes shipping simple, transparent, and efficient. A transportation logistics platform company, Fr8Hub focuses on truckload freight for domestic and cross-border markets in Mexico, the US and Canada. As an innovative digital freight marketplace, broker, transportation management system (TMS) and public API, Fr8Hub uses its proprietary technology platform to connect carriers and shippers that significantly improves matching and operation efficiency via innovative technologies such as live pricing and real-time tracking.

About Hudson Capital Inc.

Incorporated in 2014, Hudson Capital Inc. (formerly known as China Internet Nationwide Financial Services Inc. (NASDAQ: HUSN)) commenced its business by providing financial advisory services to small and medium size companies. The traditional business segments include commercial payment advisory, intermediary bank loan advisory and international corporate financing advisory services which help clients to meet their commercial payment and investment needs. For more information, about Hudson Capital, please see the documents filed by Hudson Capital with the SEC at www.sec.gov.

Important Information About the Proposed Merger Transaction and Where to Find It

In connection with the proposed merger, Hudson Capital intends to file relevant materials with the Securities and Exchange Commission (the “SEC”), including a Registration Statement on Form S-4 (the “Form S-4”) which was filed on November 12, 2020, and an amendment filed on December 31, 2020 with the SEC, and includes and serves as a proxy statement/prospectus for Hudson Capital’s shareholders and a prospectus for Fr8Hub’s stockholders. Promptly after the Form S-4 is declared effective by the SEC, Hudson Capital will mail the definitive proxy statement/prospectus and a proxy card to each shareholder entitled to vote at the special meeting on the merger and the other proposals set forth in the proxy statement. SHAREHOLDERS OF HUDSON CAPITAL ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE MERGER THAT HUDSON CAPITAL WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT HUDSON CAPITAL, FREIGHTHUB AND THE MERGER. The definitive proxy statement/prospectus and other relevant materials in connection with the merger (when they become available), and any other documents filed by Hudson Capital with the SEC, may be obtained free of charge at the SEC’s website (www.sec.gov).

Participants in the Solicitation

Hudson Capital and its directors and executive officers may be deemed participants in the solicitation of proxies from Hudson Capital’s shareholders with respect to the merger. A list of the names of those directors and executive officers and a description of their interests in Hudson Capital are included in the prospectus/proxy statement for the proposed merger and are available at www.sec.gov. Additional information regarding the interests of such participants will be contained in the prospectus/proxy statement for the proposed merger when available. Information about Hudson Capital’s directors and executive officers and their ownership of ordinary shares of Hudson Capital is set forth in Hudson Capital’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on June 15, 2020. These documents can be obtained free of charge from the sources indicated above.

Fr8Hub and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Hudson Capital in connection with the proposed merger. A list of the names of such directors and executive officers and information regarding their interests in the proposed merger are included in the prospectus/proxy statement for the proposed merger, and are available at www.sec.gov.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Hudson Capital’s and Fr8Hub’s actual results may differ from their expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Hudson Capital’s and Fr8Hub’s expectations with respect to future performance and anticipated financial impacts of the proposed acquisition, the satisfaction of the closing conditions to the proposed acquisition, and the timing of the completion of the proposed acquisition.

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Hudson Capital’s and Fr8Hub’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change, or other circumstances that could give rise to the termination of the definitive merger agreement (the “Agreement”); (2) the outcome of any legal proceedings that may be instituted against Hudson Capital or Fr8Hub following the announcement of the Agreement and the transactions contemplated therein; (3) the inability to complete the proposed acquisition, including due to failure to obtain approval of the shareholders of Hudson Capital and stockholders of Fr8Hub, certain regulatory approvals, or satisfy other conditions to closing in the Agreement; (4) the occurrence of any event, change, or other circumstance that could give rise to the termination of the Agreement or could otherwise cause the transaction to fail to close; (5) the impact of COVID-19 pandemic on Fr8Hub’s business and/or the ability of the parties to complete the proposed acquisition; (6) the inability to obtain or maintain the listing of Hudson Capital’s shares of common stock on Nasdaq following the proposed merger; (7) the risk that the proposed acquisition disrupts current plans and operations as a result of the announcement and consummation of the proposed merger; (8) the ability to recognize the anticipated benefits of the proposed merger, which may be affected by, among other things, competition, the ability of Fr8Hub to grow and manage growth profitably, and retain its key employees; (9) costs related to the proposed merger; (10) changes in applicable laws or regulations; (11) the possibility that Hudson Capital or Fr8Hub may be adversely affected by other economic, business, and/or competitive factors; (12) risks relating to the uncertainty of the projected financial information with respect to Fr8Hub; (13) risks related to the organic and inorganic growth of Fr8Hub’s business and the timing of expected business milestones; and (14) other risks and uncertainties indicated from time to time in the prospectus/proxy statement on the Form S-4, relating to the proposed merger, including those under “Risk Factors” therein, to be filed by Hudson Capital and in Hudson Capital’s other filings with the SEC. Hudson Capital cautions that the foregoing list of factors is not exclusive. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Hudson Capital and Fr8Hub caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Hudson Capital and Fr8Hub do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed merger. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Fr8Hub Contact:

Moriah Shilton or Kirsten Chapman, LHA Investor Relations, [email protected], 415.433.3777

Hudson Capital Contact:

Hon Man Yun, Chief Financial Officer, [email protected], (852) 98047102

NEWTOWN, Pa., Dec. 31, 2020 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today a 1-for-35 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time today. Beginning on January 4, 2021, the Company’s common stock will trade on The Nasdaq Capital Market and the Toronto Stock Exchange on a split adjusted basis.

Upon effectiveness, the reverse stock split will cause a reduction in the number of shares of common stock outstanding and issuable upon the conversion of the Company’s outstanding stock options and warrants in proportion to the ratio of the reverse split, and will cause a proportionate increase in the conversion and exercise prices of such stock options and warrants. Each outstanding 35 shares will be combined, converted and changed into 1 share of Common Stock, to enable the Company to comply with the Nasdaq Stock Market’s continued listing requirements. Any fraction of a share of Common Stock that would be created as a result of the Reverse Stock Split will be rounded down to the next whole share and the stockholder will receive cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of the Company’s Common Stock as reported on Nasdaq on the last trading day before the Reverse Stock Split becomes effective (on a split-adjusted basis).

The number of authorized shares of the Company’s common stock will remain at 150 million, while the number of outstanding shares will be reduced from approximately 51.9 million to approximately 1.5 million. The Company’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “HSDT” and on the Toronto Stock Exchange under the symbol “HSM.” The new CUSIP number for the common stock following the reverse split is 42328V 603.

Additional information about the reverse stock split can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 30, 2020, a copy of which is also available on the Investor Relations section of the Company’s website.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS^TM). For more information, visit www.heliusmedical.com.

Investor Relations Contact:

Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Mike Piccinino, CFA
443-213-0500
[email protected]

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Niwot, Colorado., Dec. 31, 2020 (GLOBE NEWSWIRE) — Global Healthcare REIT, Inc. (Currently in a rebranding effort to Selectis Health, Inc.) (OTC: GBCS) (“Selectis” or the “Company”) is pleased to announce financial results for the third quarter ended September 30, 2020.

THIRD QUARTER 2020 HIGHLIGHTS

• Record revenue for the third quarter of $6,320,161 (2019 $1,989,103) a growth rate of 218% year-over -year and up 23% from the previous quarter;
• Net Income of $459,177 for the second quarter (2019 $176,582) a growth rate of 160% year-over -year;
• Earnings Per Share for the second quarter of $.02 per share basic and diluted;
• Net increase in Cash of $1,486,290 to a cash balance of $4,755,441 including restricted cash for the third quarter;
• Court approved operations transfer agreement to the Company’s wholly owned subsidiary Global Eastman, LLC as the operator of the Dodge Eastman facility;
• Entered into definitive agreement to acquire the 29 licensed bed skilled nursing facility in Fairlands, Oklahoma;
• Company received a line of credit of $500,000 and a construction loan of $750,000 to be used for renovation and capital investment in its Edwards facility from Southern Bank. Both loans carry an interest rate of 4.75% on principal balance;
• On August 18, 2020, the Company’s Board of Directors approved the repurchase for redemption of 443,431 shares of common stock for $75,385 or $0.17 per share in a privately negotiated transaction. The redemption has been completed and the shares of common stock cancelled.

Lance Baller, President and CEO, said, “During the third quarter, we were able to complete a number of actions all to the benefit of the Company: we completed the operations transfer of our Eastman facility out of receivership; this is a strong property that will become a great facility for the community, and for our bottom line. The previous operator had not been paying taxes nor rent, and we were able to secure the facility and its operations at a significant discount. The Company was please it was able to negotiate in a private transaction the repurchase of shares during the quarter and at a respectable price. After being 9 months behind on financials, we are currently up to date on all SEC filings of our quarterly reports. We look forward to the completion of the corporate rebranding effort and filing our annual report. We will continue to build out the management team in the coming months to ensure our managed growth. Unfortunately, similar to others in our industry, Covid-19 was a factor during the quarter, specifically at our Tulsa facilities which resulted in a lower than anticipated impact to our census and bottom line. We had a higher-than-normal amount of write offs of bad receivables from the transfer of operations in 2019. On the whole, we are very pleased with the new direction the company is moving towards, and I look forward to 2021 and the improvements we are beginning to deploy.”

SUMMARY OF THIRD QUARTER RESULTS

GLOBAL HEALTHCARE REIT, INC.

CONSOLIDATED BALANCE SHEETS

See accompanying notes to unaudited consolidated financial statements.

GLOBAL HEALTHCARE REIT, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

For Further Information Contact:
Brandon Thall
[email protected]

HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) — Scuderia Southwest’s “Coffee and Cars” will be starting the New Year off with another high-octane event at Whitestone REIT’s Market Street at DC Ranch property in North Scottsdale, Arizona. The monthly Scottsdale Motorsports Gathering brings its collection of Ferraris, Fords, Lamborghinis, Bentleys and other rare and exotic cars back to Whitestone’s highly desirable DC Ranch property and has become a significant foot traffic driver to the property, increasing traffic 26% on the Saturdays the event is held as compared to other Saturdays in the month.

The highly anticipated event, which gathers on the first Saturday of every month, began in October at DC Ranch and kicks off again this Saturday, January 2^nd at 7am, Mountain Standard Time. Market Street at DC Ranch is located at 20789 North Pima Road, and has hosted over 150 exotic cars per event, and that number continues to grow.

Jim Mastandrea, Chairman and CEO of Whitestone REIT commented, “‘Coffee and Cars’ is quickly becoming a DC Ranch tradition as the community welcomed it with open arms when it started here in October.” Mr. Mastandrea continued,” Here at Whitestone we are always looking for new, creative, and fun events to bring into our communities. However, we admittedly did not anticipate this type of successful response so quickly! Foot traffic to our property has increased significantly, up 26%, which in turn has helped our tenants grow sales.” Mr. Mastandrea concluded, “Given the overwhelmingly positive response we have received from our Arizona neighbors, we envision hosting similar events at other Whitestone properties in our Texas markets in the future.”

About Whitestone REIT
 
Whitestone is a community-centered shopping center REIT that acquires, owns, manages, develops and redevelops high-quality neighborhood centers primarily in the largest, fastest-growing and most affluent markets in the Sunbelt. 

Whitestone seeks to create Communities That Thrive through Creating Local Connections between consumers in the surrounding communities and a well-crafted mix of national, regional and local tenants that provide daily necessities, needed services, entertainment and experiences.

Whitestone is a monthly dividend paying stock and has consistently paid dividends for over 15 years. Whitestone’s strong balanced and managed capital structure provides stability and flexibility for growth and positions Whitestone to perform well through economic cycles. For additional information, please visit www.whitestonereit.com.

About Scuderia Southwest
 
From its beginning in 2001 as a couple of guys getting coffee, to the current monthly gathering drawing hundreds of truly amazing cars, Scuderia Southwest is a group of people who share a common interest in great automobiles. We put on a few car events, organize a few drives, pull a few g’s on the track, and even congregate for a good meal. We love all cars but have a particular passion for rare exotic, high performance and collector cars and our activities typically reflect that. From the 1962 250 GTO to the latest 812 Superfast, we are passionate about Ferraris. From the 1972 Miura to the latest Aventador SV, we love Lamborghinis. The Mercedes 300 SL Gullwing and SLS AMG, McLaren 675LT, Shelby Cobra, D & E-type Jags, and Ford GT are just a few of the special cars we keep in our garages. If you’re a car guy or gal, come on out and let’s share some coffee, cool stories, and tech talk!  For additional information, please visit www.scuderiasouthwest.com .

Investors Contact:

Kevin Reed, Director of Investor Relations
Whitestone REIT
(713) 435-2219
[email protected]

SANTA BARBARA, CA , Dec. 31, 2020 (GLOBE NEWSWIRE) — SunHydrogen, Inc. (OTC:HYSR), the developer of a breakthrough technology to produce renewable hydrogen using sunlight and water, today shared an end of year business and technology development update.

The Gen 1 program was designed to provide a clear proof of concept and demonstrate the potential for scalable growth, and ultimately commercial viability. Currently, SunHydrogen is completing the build-out of the 100 prototype solar hydrogen units that include solar cell assembly with applied coatings and catalysts, and the housing for safe hydrogen collection. For the manufacturing of the solar hydrogen panels for demonstration, the Company is working with Suzhou GH New Energy Tech Co., LTD and Suzhou Maimaosi Sensor Technology Co., LTD, both based in Suzhou, China. The Gen 1 technology uses multi-junction amorphous silicon solar cells.

In 2019, the company demonstrated 1000 hours of continuous hydrogen production utilizing Gen 1 cell technology. While the overall efficiency of the cells is low, SunHydrogen has gained significant and valuable insight during experimentation for the development of its Gen 2 nanoparticle technology. SunHydrogen anticipates completing the 100 demonstration units in the beginning of Q2 of 2021, enabling the Company to leverage them as further proof of concept as the Company looks to accelerate its nano-technology development. For a more efficient use of resources, these 100 demonstration units that were previously earmarked for one large demonstration pilot plant, will be put on display as smaller demonstration centers in global locations to demonstrate how sunlight and water can be used to produce hydrogen. The infrastructure required for a large plant is well documented, and demonstrating its function with the Gen 1 panels is not relevant to the Company’s overall goal of commercializing its Gen 2 nanoparticle technology.   

SunHydrogen’s Gen 2 program is one that the Company believes is most economical from a technology and commercial viability standpoint. By gaining and leveraging insights from the Gen 1 program, Gen 2 technology is well positioned to attain three times the solar-to-hydrogen efficiency and represents a potential tipping point for market-changing hydrogen production. The Company is now working with two different companies – one in Colorado and one in Germany – that are fabricating and testing the manufacturability of Gen 2 technology structure at sizes needed for commercial viability.

“SunHydrogen has achieved a number of milestones this year spanning technology development and our capital structure, positioning us well for growth within the hydrogen fuel sector,” said Tim Young, CEO of SunHydrogen, Inc. “Well-funded and with strategic partners in place, we are laser-focused on completing the Gen 1 program and continuing to leverage our technology as a proof of concept, while adding the necessary resources and partners to advance the Gen 2 program and establish a commercial partnership. As hydrogen fuel – and more specifically green hydrogen – continues to garner attention from customers and investors alike, we anticipate 2021 being an impactful year for SunHydrogen.”

About SunHydrogen, Inc.

SunHydrogen is developing a breakthrough, low-cost technology to make renewable hydrogen using sunlight and any source of water, including seawater and wastewater. Unlike hydrocarbon fuels, such as oil, coal and natural gas, where carbon dioxide and other contaminants are released into the atmosphere when used, hydrogen fuel usage produces pure water as the only byproduct. By optimizing the science of water electrolysis at the nano-level, our low-cost nanoparticles mimic photosynthesis to efficiently use sunlight to separate hydrogen from water, ultimately producing environmentally friendly renewable hydrogen. Using our low-cost method to produce renewable hydrogen, we intend to enable a world of distributed hydrogen production for renewable electricity and hydrogen fuel cell vehicles.  To learn more about SunHydrogen, please visit our website at www.SunHydrogen.com.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and other factors detailed in reports filed by the Company with the Securities and Exchange Commission.

Press Contact:
[email protected]

TORONTO, Dec. 31, 2020 (GLOBE NEWSWIRE) — Kontrol Energy Corp. (CSE:KNR) OTCQB:KNRLF) FSE:1K8) (“Kontrol” or “Company“), a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is pleased to announce that Emerging Markets Consulting, LLC (EMC) has been retained to provide investor and public relations services. EMC specializes in helping small and mid-sized public companies establish brand awareness and increase market share to its customer base while improving visibility to the institutional and retail investment community.

“With our anticipated stock exchange uplisting in 2021 and the recent launch of BioCloud, we believe this is an opportune time to share our story with a global investor audience,” says Paul Ghezzi, CEO of Kontrol.

James Painter, President of EMC, said, “We are pleased to represent Kontrol during the coming year. We have conducted our due diligence on the Company and have been very impressed with the management, share structure and overall business strategy.”

About Emerging Markets Consulting LLC

Based in Orlando, Florida, Emerging Markets Consulting, LLC (EMC) brings over 40 years combined experience in the investor relations industry. EMC is an international investor relations firm with affiliates around the world. EMC is relationship-driven and results-oriented with the goal of seeking attractive emerging companies and concentrating its resources and efforts to serve a limited number of high-quality clients. For more information, visit EMC’s website at www.emergingmarketsllc.com

About Kontrol BioCloud

^TM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.

About Kontrol Energy

Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com                    

https://www.facebook.com/kontrolenergy

https://twitter.com/kontrolenergy

https://www.linkedin.com/company/kontrol-energy-corp

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Emerging Markets Consulting, LLC
James S. Painter, CEO
390 North Orange Ave Suite 2300
Orlando, Florida 32801
E-mail: [email protected]
Web: www.emergingmarketsllc.com

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.